For example, gangliocytoma show mutations in BRAF, KRAS, RAF1, NF1 (neurofibromin 1) and CDKN2A (cyclin dependent kinase inhibitor 2A) (251) and tumors of the glia in FGFR, HRAS, BRAF and NF1 (100). This evidence concerns the gene NF1 and gangliocytoma.